FSN Capital completed the acquisition of a majority stake in Adragos Pharma from Prange Group.

FSN Capital, a Northern European private equity investment firm, completed the acquisition of a majority stake in Adragos Pharma, a growing B2B contract developer and manufacturer for pharmaceuticals, from Prange Group, a family office with majority ownership in more than 60 companies. Financial terms were not disclosed. "The Group has an excellent market position based on well-established production sites that enjoyed double-digit growth rates in recent years, significantly above the general CDMO market. This is a result of a high level of service and care for our customers. Now we can take the next step and realize our vision of becoming a global leader," Andreas Raabe, Adragos CEO.